Improving access to Alzheimer’s PET imaging for better clinical trials.
Official title: Enabling nationwide AD PET imaging to support most efficient clinical trials by adoption of radically simplified and standardized quality control in commercial production of AD PET tracers.
Funded at Trace-Ability, INC. · NIH-11163546 · Data updated 2026-11-12
This study is working on making a special type of brain scan for Alzheimer’s disease easier and quicker to produce, so that more patients can get the help they need and researchers can run better clinical trials.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Trace-Ability, INC. NIH-funded |
| Lab location | 1 site (Van Nuys, United States) |
| Project start | February 1, 2021 |
| Project end | April 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $1,499,998 |
| NIH project number | 5R44AG071409-04 |
| Project ID | NIH-11163546 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer’s disease or those at risk of developing it who may benefit from advanced imaging techniques.
✕Less likely to help
Patients with other forms of dementia or cognitive impairment unrelated to Alzheimer’s disease may not receive direct benefits from this research.
What this research studies
This research focuses on enhancing the availability of Positron Emission Tomography (PET) imaging for Alzheimer’s disease by simplifying and standardizing the production of PET tracers. The project aims to develop a new quality control method that uses innovative optical measurements, making it easier and faster to produce these tracers on a larger scale. By ensuring that these tracers are readily available, the research seeks to support more efficient clinical trials and improve patient outcomes in Alzheimer’s disease management.
Why it matters
Potential benefit: If successful, this research could significantly increase the availability of PET imaging for Alzheimer’s disease, leading to earlier detection and better treatment options for patients.
How similar studies have gone: Previous research has shown promise in improving imaging techniques for Alzheimer’s disease, but this approach to standardizing production and quality control is relatively novel.
Where this research is happening
-
Trace-Ability, INC.
Van Nuys, United States Active
Researchers
- Principal investigator: Elizarov, Arkadij — Trace-Ability, INC.
- Study coordinator: Elizarov, Arkadij
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.